Mirna Therapeutics Company Profile (NASDAQ:MIRN)

About Mirna Therapeutics

Mirna Therapeutics logoMirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company's RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MIRN
  • CUSIP:
Key Metrics:
  • Previous Close: $2.33
  • 50 Day Moving Average: $2.089
  • 200 Day Moving Average: $2.127
  • 52-Week Range: $20,835,000.00 - $1.12
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.69
  • P/E Growth: 0.000
  • Market Cap: $48.44M
  • Outstanding Shares: 20,835,000
  • Beta: 3.82
Profitability:
  • Return on Equity: -34.47%
  • Return on Assets: -32.77%
Debt:
  • Current Ratio: 21.71%
  • Quick Ratio: 21.71%
Additional Links:
Companies Related to Mirna Therapeutics:

Analyst Ratings

Consensus Ratings for Mirna Therapeutics (NASDAQ:MIRN) (?)
Ratings Breakdown: 5 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $4.10 (76.34% upside)

Analysts' Ratings History for Mirna Therapeutics (NASDAQ:MIRN)
Show:
DateFirmActionRatingPrice TargetDetails
11/15/2016HC WainwrightReiterated RatingHoldView Rating Details
9/22/2016Citigroup Inc.Lower Price TargetNeutral$4.50 -> $2.00View Rating Details
9/21/2016Leerink SwannReiterated RatingHold -> Neutral$4.00 -> $1.50View Rating Details
9/21/2016Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformView Rating Details
9/21/2016Cantor FitzgeraldDowngradeBuy -> Hold$14.00 -> $2.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Mirna Therapeutics (NASDAQ:MIRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2017        
11/13/2015Q315($82.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mirna Therapeutics (NASDAQ:MIRN)
Current Year EPS Consensus Estimate: $-1.130 EPS
Next Year EPS Consensus Estimate: $-0.630 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.43)($0.43)($0.43)
Q2 20162($0.50)($0.43)($0.47)
Q3 20162($0.38)($0.29)($0.34)
Q4 20162($0.59)($0.29)($0.44)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Mirna Therapeutics (NASDAQ:MIRN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mirna Therapeutics (NASDAQ:MIRN)
Insider Ownership Percentage: 18.60%
Institutional Ownership Percentage: 28.38%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2016Jon IrvinVPSell280$1.43$400.40View SEC Filing  
11/1/2016Jon IrvinVPSell280$1.28$358.40View SEC Filing  
10/11/2016Jon IrvinVPSell150$1.83$274.50View SEC Filing  
10/3/2016Jon IrvinVPSell250$1.93$482.50View SEC Filing  
10/6/2015Michael PowellDirectorBuy857,142$7.00$5,999,994.00View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Mirna Therapeutics (NASDAQ:MIRN)
DateHeadline
News IconMirna Therapeutics Inc MIRN Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:MIRN)
www.bioportfolio.com - February 18 at 5:46 PM
News IconMiddle-East and Africa Multiple Myeloma Therapeutics Market Segmentation By Treatment Type and By Drug Type (NASDAQ:MIRN)
emailwire.com - February 14 at 5:46 AM
News IconMirna Therapeutics Inc MIRN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:MIRN)
www.bioportfolio.com - January 28 at 12:09 AM
News IconEquities Analysts Offer Predictions for Mirna Therapeutics, Inc.’s FY2016 Earnings (MIRN) (NASDAQ:MIRN)
forextv.com - January 14 at 6:38 PM
bizjournals.com logoTexas Innovations in Health Care: More Austin biotech companies go public, but hit stock turbulence (NASDAQ:MIRN)
www.bizjournals.com - December 8 at 7:08 PM
finance.yahoo.com logoMIRNA THERAPEUTICS, INC. Financials (NASDAQ:MIRN)
finance.yahoo.com - November 24 at 9:26 AM
kcregister.com logoStephan Tanda has been appointed by AptarGroup, Inc. (NYSE:ATR) As President and CEO (NASDAQ:MIRN)
www.kcregister.com - November 23 at 6:14 PM
4-traders.com logoMirna Therapeutics : Reports Third Quarter 2016 Financial Results and MRX34 Clinical Program Updates (NASDAQ:MIRN)
www.4-traders.com - November 22 at 6:19 PM
marketexclusive.com logoHC Wainwright Reiterates Hold on Mirna Therapeutics (NASDAQ:MIRN) (NASDAQ:MIRN)
marketexclusive.com - November 15 at 6:47 PM
bizjournals.com logoCentral Texas company halts cancer drug trial after deaths (NASDAQ:MIRN)
www.bizjournals.com - November 14 at 6:31 PM
4-traders.com logoMirna Therapeutics : reports 3Q loss (NASDAQ:MIRN)
www.4-traders.com - November 11 at 5:52 PM
bizjournals.com logoAustin cancer fighters halt drug development after deaths (NASDAQ:MIRN)
www.bizjournals.com - November 11 at 5:52 PM
reuters.com logoBRIEF-Mirna therapeutics qtrly net loss was about $5.4 mln (NASDAQ:MIRN)
www.reuters.com - November 11 at 8:35 AM
sg.finance.yahoo.com logoMirna Therapeutics reports 3Q loss (NASDAQ:MIRN)
sg.finance.yahoo.com - November 11 at 8:35 AM
publicnow.com logoMirna Therapeutics Reports Third Quarter 2016 Financial Results and MRX34 Clinical Program Updates (NASDAQ:MIRN)
www.publicnow.com - November 10 at 5:52 PM
News IconNasopharyngeal Cancer Pipeline H2 2016 Market Report (NASDAQ:MIRN)
www.medindia.net - October 14 at 9:27 AM
4-traders.com logoMIRNA THERAPEUTICS, INC. : Other Events (form 8-K) (NASDAQ:MIRN)
www.4-traders.com - September 29 at 6:07 PM
biz.yahoo.com logoMIRNA THERAPEUTICS, INC. Files SEC form 8-K, Other Events (NASDAQ:MIRN)
biz.yahoo.com - September 29 at 6:07 PM
News IconNew study: Global metastatic hepatocellular carcinoma (HCC) pipeline 2016 market research (NASDAQ:MIRN)
www.whatech.com - September 27 at 6:02 PM
News IconHere's Why Mirna Therapeutics Inc Shares Are Falling 24% (NASDAQ:MIRN)
magseriesusa.net - September 24 at 10:34 AM
News IconMirna Therapeutics' (MIRN) Neutral Rating Reaffirmed at Leerink Swann (NASDAQ:MIRN)
thelakeandeswave.com - September 24 at 10:34 AM
stockhouse.com logoMirna's Murky Clinical Strategy Leaves HC Wainwright Hesitant (NASDAQ:MIRN)
www.stockhouse.com - September 23 at 10:50 AM
streetinsider.com logoMirna Therapeutics (MIRN) Halts Clinical Study of MRX34 Following Severe Adverse Events (NASDAQ:MIRN)
www.streetinsider.com - September 22 at 5:53 PM
News IconToxicity troubles halt Mirna's phase I trial of microRNA mimic MRX34 (NASDAQ:MIRN)
www.bioworld.com - September 22 at 5:53 PM
businesswire.com logoMirna Therapeutics Halts Phase 1 Clinical Study of MRX34 (NASDAQ:MIRN)
www.businesswire.com - September 22 at 5:53 PM
finance.yahoo.com logoMirna Hits a New Low After Halting Clinical Trial (NASDAQ:MIRN)
finance.yahoo.com - September 21 at 5:50 PM
finance.yahoo.com logoMirna Therapeutics (MIRN) Is in Oversold Territory: What's Next? (NASDAQ:MIRN)
finance.yahoo.com - September 13 at 10:58 AM
stockhouse.com logoH.C. Wainwright Initiates Mirna At Buy, Sees 135% Upside (NASDAQ:MIRN)
www.stockhouse.com - September 12 at 5:54 PM
publicnow.com logoMirna Therapeutics to Participate in Two Healthcare Investor Conferences in September (NASDAQ:MIRN)
www.publicnow.com - August 31 at 11:04 AM
finance.yahoo.com logoValue Screeners Identify Cheap Company Stocks (NASDAQ:MIRN)
finance.yahoo.com - August 29 at 6:03 PM
finance.yahoo.com logoMirna Therapeutics downgraded by Leerink Partners (NASDAQ:MIRN)
finance.yahoo.com - August 16 at 6:20 PM
reuters.com logoBRIEF-Mirna Therapeutics qtrly net loss attributable to common stockholders $5.64 mln (NASDAQ:MIRN)
www.reuters.com - August 15 at 8:24 AM
News IconMirna Therapeutics Reports Second Quarter 2016 Financial Results and Program Updates (NASDAQ:MIRN)
ih.advfn.com - August 15 at 8:24 AM
4-traders.com logoMIRNA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:MIRN)
www.4-traders.com - August 15 at 8:24 AM
sg.finance.yahoo.com logoMirna Therapeutics reports 2Q loss (NASDAQ:MIRN)
sg.finance.yahoo.com - August 15 at 8:23 AM
businesswire.com logomiRagen Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:MIRN)
www.businesswire.com - August 11 at 9:21 AM
biz.yahoo.com logoMIRNA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:MIRN)
biz.yahoo.com - July 6 at 5:19 PM
publicnow.com logoMirna Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:MIRN)
www.publicnow.com - July 5 at 7:21 AM
finance.yahoo.com logoMirna Therapeutics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference (NASDAQ:MIRN)
finance.yahoo.com - July 5 at 7:00 AM
4-traders.com logoMIRNA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders (form 8-K) (NASDAQ:MIRN)
www.4-traders.com - July 1 at 6:11 PM
biz.yahoo.com logoMIRNA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of Matters to a V (NASDAQ:MIRN)
biz.yahoo.com - June 30 at 5:30 PM
publicnow.com logoMirna Therapeutics Appoints Perry Nisen, M.D., Ph.D., to Its Board of Directors (NASDAQ:MIRN)
www.publicnow.com - June 30 at 7:21 AM
capitalcube.com logoMirna Therapeutics, Inc. :MIRN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 (NASDAQ:MIRN)
www.capitalcube.com - June 8 at 6:07 PM
publicnow.com logoMirna Therapeutics Announces Clinical Data on its Lead microRNA Therapeutic Presented at ASCO (NASDAQ:MIRN)
www.publicnow.com - June 6 at 12:28 PM
bizjournals.com logoAustin-area Public Companies list (NASDAQ:MIRN)
www.bizjournals.com - June 3 at 8:58 AM
marketwired.com logoMarina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French (NASDAQ:MIRN)
www.marketwired.com - June 2 at 6:32 PM
tmcnet.com logomiRagen Therapeutics Receives ALS Association Grant to Advance the Development of MRG-107 (NASDAQ:MIRN)
www.tmcnet.com - June 2 at 9:04 AM
sg.finance.yahoo.com logoMirna Therapeutics reports 1Q loss (NASDAQ:MIRN)
sg.finance.yahoo.com - May 12 at 6:52 PM
publicnow.com logoMirna Therapeutics Reports First Quarter 2016 Financial Results and Program Updates (NASDAQ:MIRN)
www.publicnow.com - May 12 at 5:27 PM
marketwired.com logoMarina Biotech Terminates Negotiations for Sale of Its Nucleic Acid Therapeutic Assets (NASDAQ:MIRN)
www.marketwired.com - May 3 at 11:35 AM

Social

What is Mirna Therapeutics' stock symbol?

Mirna Therapeutics trades on the NASDAQ under the ticker symbol "MIRN."

Where is Mirna Therapeutics' stock going? Where will Mirna Therapeutics' stock price be in 2017?

5 equities research analysts have issued 12-month price targets for Mirna Therapeutics' shares. Their predictions range from $1.50 to $13.00. On average, they expect Mirna Therapeutics' stock price to reach $4.10 in the next twelve months.

When will Mirna Therapeutics announce their earnings?

Mirna Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.

What are analysts saying about Mirna Therapeutics stock?

Here are some recent quotes from research analysts about Mirna Therapeutics stock:

  • According to Zacks Investment Research, "Mirna Therapeutics, Inc. is a biopharmaceutical company which develops microRNA-based oncology therapeutics. The Company's pipeline products include MRX34, miR-Rxlet-7, miR-Rx06, miR-Rx07 and miR-Rx16 which are in preclinical trials. Its lead product, MRX34, is a liposome-encapsulated miR-34 mimic indicated for the treatment of primary liver cancer, solid cancers with liver metastases and hematological malignancies. Mirna Therapeutics, Inc. is headquartered in Austin, Texas. " (1/17/2017)

  • Leerink Swann analysts commented, "We maintain our Market Perform rating for Amgen along with our $193 price target." (9/21/2016)

Who owns Mirna Therapeutics stock?

Mirna Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (6.64%) and FMR LLC (0.64%). Company insiders that own Mirna Therapeutics stock include Jon Irvin, Michael Powell and Pfizer Inc.

Who sold Mirna Therapeutics stock? Who is selling Mirna Therapeutics stock?

Mirna Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Franklin Resources Inc..

How do I buy Mirna Therapeutics stock?

Shares of Mirna Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Mirna Therapeutics stock cost?

One share of Mirna Therapeutics stock can currently be purchased for approximately $2.33.

Mirna Therapeutics (NASDAQ:MIRN) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Mirna Therapeutics (NASDAQ:MIRN)

Earnings History Chart

Earnings by Quarter for Mirna Therapeutics (NASDAQ:MIRN)

Dividend History Chart

Dividend Payments by Quarter for Mirna Therapeutics (NASDAQ:MIRN)

Last Updated on 2/19/2017 by MarketBeat.com Staff